PAT 409

Drug Profile

PAT 409

Alternative Names: PAT-409

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmAkea Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Skin disorder therapies
  • Mechanism of Action ENPP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cholangitis; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases; Kidney disorders; Non-alcoholic steatohepatitis; Scleroderma

Most Recent Events

  • 20 Nov 2017 Preclinical trials in Inflammatory bowel disease in USA before November 2017 (PharmAkea Therapeutics pipeline, November 2017)
  • 20 Oct 2017 Pharmacodynamics data from a preclinical trial in non-alcoholic steatohepatitis presented at the The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 22 Aug 2017 Preclinical trials in Cholangitis in USA before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top